Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress

Core Insights - Zura Bio Limited is set to present the design of its Phase 2 TibuSURE clinical trial for tibulizumab in systemic sclerosis at the 9th Systemic Sclerosis World Congress in March 2026 [1] - The TibuSURE trial aims to evaluate the dual inhibition of IL-17A and BAFF, targeting a rare autoimmune disease with limited treatment options [1] - The study will enroll approximately 80 adults, randomized to receive either tibulizumab or placebo, with primary endpoints focused on skin score changes [1] Company Overview - Zura Bio is a clinical-stage biotechnology company focused on developing innovative treatments for autoimmune and inflammatory diseases [1] - The company's lead product candidate, tibulizumab (ZB-106), is also being evaluated in another Phase 2 study for hidradenitis suppurativa [1] - Zura's pipeline includes additional candidates targeting various autoimmune conditions, with a goal of improving treatment efficacy and safety [1] Clinical Trial Details - The TibuSURE trial is a multi-center, randomized, double-blind, placebo-controlled study with an open-label extension [1] - The primary endpoint is the change in modified Rodnan Skin Score at Week 24, with topline results expected in the first half of 2027 [1] - The trial represents a novel approach by targeting both inflammatory and fibrotic processes in systemic sclerosis [1]